Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

@article{Sequist2016OsimertinibRA,
  title={Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.},
  author={Lecia V Sequist and Zofia Piotrowska and Matthew J. Niederst and Rebecca Suk Heist and Subba R Digumarthy and Alice Tsang Shaw and Jeffrey A. Engelman},
  journal={JAMA oncology},
  year={2016},
  volume={2 4},
  pages={541-3}
}
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib Third-generation EGFR tyrosine kinase inhibitors (TKIs) that block activating EGFR mutations and the T790M resistance mutation yield marked responses among patients with EGFR mutation–positive lung cancer and acquired resistance to initial TKIs.1,2 Osimertinib (formerly AZD9291) was recently approved by the US Food and Drug Administration, and rociletinib (formerly CO-1686) is under regulatory… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2017
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…